Excess Cardiovascular Risk in Women Relative to Men Referred for Coronary Angiography Is Associated With Severely Impaired Coronary Flow Reserve, Not Obstructive Disease

Background: Cardiovascular disease (CVD) fatality rates are higher for women than for men, yet obstructive coronary artery disease (CAD) is less prevalent in women. Coronary flow reserve (CFR), an integrated measure of large- and small-vessel CAD and myocardial ischemia, identifies patients at risk for CVD death, but is not routinely measured in clinical practice. We sought to investigate the impact of sex, CFR, and angiographic CAD severity on adverse cardiovascular events. Methods: Consecutive patients (n=329, 43% women) referred for invasive coronary angiography after stress testing with myocardial perfusion positron emission tomography and with left ventricular ejection fraction >40% were followed (median, 3.0 years) for a composite end point of major adverse cardiovascular events, including cardiovascular death and hospitalization for nonfatal myocardial infarction or heart failure. The extent and severity of angiographic CAD were estimated by using the CAD prognostic index, and CFR was quantified by using positron emission tomography. Results: Although women in comparison with men had lower pretest clinical scores, rates of prior myocardial infarction, and burden of angiographic CAD (P<0.001), they demonstrated greater risk of CVD events, even after adjustment for traditional risk factors, imaging findings, and early revascularization (adjusted hazard ratio, 2.05; 95% confidence interval, 1.05–4.02; P=0.03). Impaired CFR was similarly present among women and men, but in patients with low CFR (<1.6, n=163), women showed a higher frequency of nonobstructive CAD, whereas men showed a higher frequency of severely obstructive CAD (P=0.002). After also adjusting for CFR, the effect of sex on outcomes was no longer significant. When stratified by sex and CFR, only women with severely impaired CFR demonstrated significantly increased adjusted risk of CVD events (P<0.0001, P for interaction=0.04). Conclusions: Women referred for coronary angiography had a significantly lower burden of obstructive CAD in comparison with men but were not protected from CVD events. Excess cardiovascular risk in women was independently associated with impaired CFR, representing a hidden biological risk, and a phenotype less amenable to revascularization. Impaired CFR, particularly absent severely obstructive CAD, may represent a novel target for CVD risk reduction.

[1]  Robert Califf,et al.  Value of the History and Physical in Identifying Patients at Increased Risk for Coronary Artery Disease , 1993, Annals of Internal Medicine.

[2]  F. Harrell,et al.  Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. , 1994, Circulation.

[3]  James T. Willerson,et al.  Appointment of New Associate Editor for Circulation , 1996 .

[4]  J. Willerson Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. , 1996, Circulation.

[5]  Robert L. Frye,et al.  Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. , 1996, The New England journal of medicine.

[6]  R. Virmani,et al.  Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. , 1998, Circulation.

[7]  O Muzik,et al.  Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. , 1999, Circulation.

[8]  M. Cerqueira,et al.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. , 2002, Circulation.

[9]  D. Berman,et al.  Comparison of the Short‐Term Survival Benefit Associated With Revascularization Compared With Medical Therapy in Patients With No Prior Coronary Artery Disease Undergoing Stress Myocardial Perfusion Single Photon Emission Computed Tomography , 2003, Circulation.

[10]  K. Smith,et al.  Abnormal Coronary Vasomotion as a Prognostic Indicator of Cardiovascular Events in Women: Results From the National Heart, Lung, and Blood Institute–Sponsored Women’s Ischemia Syndrome Evaluation (WISE) , 2004, Circulation.

[11]  Carl J Pepine,et al.  Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. , 2006, Journal of the American College of Cardiology.

[12]  Georges El Fakhri,et al.  Reproducibility and Accuracy of Quantitative Myocardial Blood Flow Assessment with 82Rb PET: Comparison with 13N-Ammonia PET , 2009, Journal of Nuclear Medicine.

[13]  Carl J Pepine,et al.  Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. , 2009, Archives of internal medicine.

[14]  C. Noel Bairey Merz,et al.  Women and ischemic heart disease: evolving knowledge. , 2009, Journal of the American College of Cardiology.

[15]  Oliver Gaemperli,et al.  Long-term prognostic value of 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. , 2009, Journal of the American College of Cardiology.

[16]  Antonio Colombo,et al.  Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. , 2009, The New England journal of medicine.

[17]  Maria Mori Brooks,et al.  A randomized trial of therapies for type 2 diabetes and coronary artery disease. , 2009, The New England journal of medicine.

[18]  S. Kelsey,et al.  A randomized controlled trial of low-dose hormone therapy on myocardial ischemia in postmenopausal women with no obstructive coronary artery disease: results from the National Institutes of Health/National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE). , 2010, American heart journal.

[19]  P. Libby,et al.  Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). , 2011, American heart journal.

[20]  B. Borlaug,et al.  Why are women more likely than men to develop heart failure with preserved ejection fraction? , 2011, Current opinion in cardiology.

[21]  M. Pencina,et al.  Improved Cardiac Risk Assessment With Noninvasive Measures of Coronary Flow Reserve , 2011, Circulation.

[22]  J. Hochman,et al.  Women have less severe and extensive coronary atherosclerosis in fatal cases of ischemic heart disease: an autopsy study. , 2011, American heart journal.

[23]  M. Javadi,et al.  Prediction of Short-Term Cardiovascular Events Using Quantification of Global Myocardial Flow Reserve in Patients Referred for Clinical 82Rb PET Perfusion Imaging , 2011, The Journal of Nuclear Medicine.

[24]  Kathryn A. Williams,et al.  Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia. , 2011, Journal of the American College of Cardiology.

[25]  R. Blankstein,et al.  Association Between Coronary Vascular Dysfunction and Cardiac Mortality in Patients With and Without Diabetes Mellitus , 2012, Circulation.

[26]  S. Solomon,et al.  Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients With Stable Coronary Disease , 2012, Circulation.

[27]  Akshay S. Desai,et al.  Strategies for multivessel revascularization in patients with diabetes. , 2012, The New England journal of medicine.

[28]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[29]  Juhani Knuuti,et al.  Anatomic versus physiologic assessment of coronary artery disease. Role of coronary flow reserve, fractional flow reserve, and positron emission tomography imaging in revascularization decision-making. , 2013, Journal of the American College of Cardiology.

[30]  O. Rimoldi,et al.  Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease. , 2013, JACC. Cardiovascular imaging.

[31]  M. Shishehbor,et al.  Strategies for multivessel revascularization in patients with diabetes , 2013 .

[32]  P. Libby,et al.  Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. , 2013, American heart journal.

[33]  F. Rybicki,et al.  Prognostic Value of Nonobstructive and Obstructive Coronary Artery Disease Detected by Coronary Computed Tomography Angiography to Identify Cardiovascular Events , 2014, Circulation. Cardiovascular imaging.

[34]  C. B. Bairey Merz Sex, death, and the diagnosis gap. , 2014, Circulation.

[35]  C. N. Merz Sex, Death, and the Diagnosis Gap , 2014 .

[36]  O. Rimoldi,et al.  Effects of Sex on Coronary Microvascular Dysfunction and Cardiac Outcomes , 2014, Circulation.

[37]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[38]  R. Blankstein,et al.  Interaction of Impaired Coronary Flow Reserve and Cardiomyocyte Injury on Adverse Cardiovascular Outcomes in Patients Without Overt Coronary Artery Disease , 2015, Circulation.

[39]  M. Walsh,et al.  Emergence of Nonobstructive Coronary Artery Disease: A Woman's Problem and Need for Change in Definition on Angiography. , 2015, Journal of the American College of Cardiology.

[40]  R. Blankstein,et al.  Global Coronary Flow Reserve Is Associated With Adverse Cardiovascular Events Independently of Luminal Angiographic Severity and Modifies the Effect of Early Revascularization , 2015, Circulation.

[41]  E. Braunwald The war against heart failure: the Lancet lecture , 2015, The Lancet.

[42]  M. Jessup,et al.  "Frailty, thy name is woman": syndrome of women with heart failure with preserved ejection fraction. , 2015, Circulation. Cardiovascular quality and outcomes.

[43]  Jennifer G. Robinson,et al.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[44]  K. Rexrode,et al.  Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus: A Scientific Statement From the American Heart Association. , 2015, Circulation.

[45]  Ryotaro Yamada,et al.  Invasive Evaluation of Patients With Angina in the Absence of Obstructive Coronary Artery Disease , 2015, Circulation.

[46]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[47]  Tyler J VanderWeele,et al.  eAppendix for : ” SAS macro for causal mediation analysis with survival data ” , 2014 .

[48]  Mark D. Huffman,et al.  AHA Statistical Update Heart Disease and Stroke Statistics — 2012 Update A Report From the American Heart Association WRITING GROUP MEMBERS , 2010 .

[49]  D. Berman,et al.  Prognostic and Therapeutic Implications of Statin and Aspirin Therapy in Individuals With Nonobstructive Coronary Artery Disease: Results From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter Registry) Registry , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[50]  Eric E. Smith,et al.  Sex and Race/Ethnicity–Related Disparities in Care and Outcomes After Hospitalization for Coronary Artery Disease Among Older Adults , 2016, Circulation. Cardiovascular quality and outcomes.

[51]  K. Schenck-Gustafsson,et al.  Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. , 2016, European heart journal.